A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Clinical trial NCT07554456 · RECRUITING
Trial details
- NCT number
- NCT07554456
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-09
- Primary completion
- 2028-12-01
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.